Skip to content

Risperidone versus olanzapine for treatment of patients with schizophrenia

Risperidone versus olanzapine for treatment of patients with schizophrenia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201709285147N3
Enrollment
35
Registered
2017-10-03
Start date
2016-03-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia.

Interventions

The patients divide to 2groups 1- the patients on Risperidone 4 mg t0 24 mg p.o. 2- patients on Olanzapine 10 mg t0 45mg.
Treatment - Drugs
The patients divide to 2groups 1- the patients on Risperidone 4 mg t0 24 mg p.o. 2- patients on Olanzapine 10 mg t0 45mg

Sponsors

Vice chanseller of Yasuj University of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patients with schizophrenia are based on history, MSE, physical exam and DSMIV criteria. PANSS done at the first day of study. Before the starts of study the patients do not have to receive any drug, no pregnant and full cooperation until end of study. The patients exclude if have no any of above condition, or the existence of any side effect.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Interview- MSE-PANSS-CGI-SAS. Timepoint: Start day of study-1 month after start- 2 months after start. Method of measurement: Interview based on DSMIV- MSE-PANSS-CGI-SAS.

Secondary

MeasureTime frame
Interview-PANSS-CGI-SAS. Timepoint: start day-1 mont dayh after start day-2 month after start. Method of measurement: interview based on DSMIV-PANSS-CGI-SAS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazir Hashemi Mohammad Abad

Yasuj University of Medical Sciences

nazir.hashemi@gmail.com+98 74133222291

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026